Results from Ph 2 POC study of HLX43 in recurrent/metastatic cervical cancer published
By the data cutoff date of September 1, 2025, 30 patients were enrolled and randomized to receive HLX43 at 2 mg/kg (n=10), 2.5 mg/kg (n=10) and 3 mg/kg (n=10). Over 80% of the patients had a PD-L1 combined positive score ≥ 1. The median line of prior antitumor therapy was 2.0 (range, 1–4). All patients received platinum-based chemotherapy, 60% received targeted therapy, approximately 50% received immunotherapy, and the median follow-up time was 3.5 months. Among the 29 response evaluable patients, investigator-assessed ORR was 41.4% and disease control rate (DCR) was 82.8%. ORR, and DCR for the 3 mg/kg dose group was 70.0%, and 100%, respectively. The median Progression-Free Survival (PFS) has not yet been reached.
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo